|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
KR20050118669A
(ko)
*
|
2003-02-01 |
2005-12-19 |
뉴랄랩 리미티드 |
가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
|
|
TWI306458B
(en)
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
|
EA200700751A1
(ru)
*
|
2004-10-05 |
2008-06-30 |
Элан Фарма Интернэшнл Лимитед |
Способы и композиции для улучшения продуцирования рекомбинантного белка
|
|
ES2396555T3
(es)
|
2004-12-15 |
2013-02-22 |
Janssen Alzheimer Immunotherapy |
Anticuerpos que reconocen péptido beta amiloide
|
|
EP1838348B1
(en)
|
2004-12-15 |
2013-06-26 |
Janssen Alzheimer Immunotherapy |
Humanized amyloid beta antibodies for use in improving cognition
|
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
BRPI0611600B8
(pt)
*
|
2005-06-17 |
2021-05-25 |
Wyeth Corp |
método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
|
|
TW200806317A
(en)
*
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
CN101553504A
(zh)
*
|
2006-12-11 |
2009-10-07 |
豪夫迈·罗氏有限公司 |
Aβ抗体胃肠外制剂
|
|
ES2610474T3
(es)
|
2007-01-11 |
2017-04-27 |
Michael Bacher |
Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
|
|
CA2681752A1
(en)
|
2007-03-29 |
2008-10-09 |
Abbott Laboratories |
Crystalline anti-human 1l-12 antibodies
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
ES2498040T3
(es)
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
US8796206B2
(en)
*
|
2007-11-15 |
2014-08-05 |
Amgen Inc. |
Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
US8420081B2
(en)
*
|
2007-11-30 |
2013-04-16 |
Abbvie, Inc. |
Antibody formulations and methods of making same
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
PT2993186T
(pt)
|
2008-03-14 |
2019-11-29 |
Biocon Ltd |
Anticorpo monoclonal e um método do mesmo
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
EP2196476A1
(en)
*
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
EP2403873A1
(en)
*
|
2009-03-05 |
2012-01-11 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
|
WO2011008770A2
(en)
*
|
2009-07-14 |
2011-01-20 |
Biogen Idec Ma Inc. |
Methods for inhibiting yellow color and peroxide formation in a composition
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
EP2519539A4
(en)
*
|
2009-12-28 |
2013-11-13 |
Ligocyte Pharmaceuticals Inc |
METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
|
|
US20110158987A1
(en)
*
|
2009-12-29 |
2011-06-30 |
F. Hoffmann-Laroche Ag |
Novel antibody formulation
|
|
PT2542257T
(pt)
|
2010-03-01 |
2017-10-09 |
Bayer Healthcare Llc |
Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
|
|
WO2011121306A1
(en)
|
2010-03-31 |
2011-10-06 |
Stabilitech Ltd. |
Stabilisation of viral particles
|
|
JP5869553B2
(ja)
|
2010-03-31 |
2016-02-24 |
スタビリテック リミテッド |
ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
|
|
DK2552410T3
(en)
|
2010-03-31 |
2019-02-18 |
Stabilitech Biopharma Ltd |
PROCEDURE FOR THE CONSERVATION OF ALUNADUVANCES AND VACCINES WITH ALUNADUVANCES
|
|
EP3626263A1
(en)
|
2010-06-04 |
2020-03-25 |
Wyeth LLC |
Vaccine formulations
|
|
TWI603739B
(zh)
|
2010-11-11 |
2017-11-01 |
艾伯維生物技術有限責任公司 |
具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
|
|
EP2471554A1
(en)
*
|
2010-12-28 |
2012-07-04 |
Hexal AG |
Pharmaceutical formulation comprising a biopharmaceutical drug
|
|
EP2500035A1
(en)
*
|
2011-03-15 |
2012-09-19 |
Icon Genetics GmbH |
Pharmaceutical formulation containing immunglobulin
|
|
WO2012135408A1
(en)
|
2011-03-31 |
2012-10-04 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
|
|
GB201117233D0
(en)
|
2011-10-05 |
2011-11-16 |
Stabilitech Ltd |
Stabilisation of polypeptides
|
|
AU2013287119A1
(en)
*
|
2012-07-03 |
2015-01-22 |
Janssen Alzheimer Immunotherapy |
C-terminal and central epitope a-beta antibodies
|
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
US10189899B2
(en)
|
2013-07-23 |
2019-01-29 |
Biocon Limited |
Use of a CD6 binding partner and method based thereon
|
|
IL312865B2
(en)
*
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
GB201320660D0
(en)
*
|
2013-11-22 |
2014-01-08 |
Qualasept Ltd |
Method
|
|
GB201406569D0
(en)
|
2014-04-11 |
2014-05-28 |
Stabilitech Ltd |
Vaccine compositions
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
AR104847A1
(es)
*
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
AU2016282334B2
(en)
|
2015-06-24 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies with tailored affinity
|
|
MX2018003822A
(es)
|
2015-10-02 |
2018-06-22 |
Hoffmann La Roche |
Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
GB201604124D0
(en)
*
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
|
CN107446044B
(zh)
*
|
2016-05-30 |
2021-04-30 |
越海百奥药业(绍兴)有限公司 |
一种纯化抗体的方法及所用缓冲液
|
|
WO2018025128A1
(en)
|
2016-08-02 |
2018-02-08 |
Jamil Irfan |
Stable ibuprofen injectable composition
|
|
KR102514528B1
(ko)
|
2016-10-21 |
2023-03-27 |
바이오콘 리미티드 |
루푸스 치료를 위한 단일클론항체 및 이의 치료방법
|
|
GB201703063D0
(en)
|
2017-02-24 |
2017-04-12 |
Arecor Ltd |
Stabilized antibody protein solutions
|
|
US11608357B2
(en)
|
2018-08-28 |
2023-03-21 |
Arecor Limited |
Stabilized antibody protein solutions
|
|
EP3372242A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
EP3372241A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
CN110913906A
(zh)
|
2017-05-02 |
2020-03-24 |
默沙东公司 |
抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
|
|
GB2562241B
(en)
|
2017-05-08 |
2022-04-06 |
Stabilitech Biopharma Ltd |
Vaccine compositions
|
|
MD3672631T3
(ro)
*
|
2017-08-22 |
2023-09-30 |
Biogen Ma Inc |
Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
|
|
MA51032A
(fr)
|
2017-12-08 |
2021-03-17 |
Argenx Bvba |
Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
|
|
JP7486437B2
(ja)
*
|
2018-06-08 |
2024-05-17 |
アルジェニクス ビーブイ |
免疫性血小板減少症を治療する組成物及び方法
|
|
MX2021004356A
(es)
|
2018-10-18 |
2021-05-31 |
Merck Sharp & Dohme Llc |
Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
|
|
MA54089A
(fr)
|
2018-10-31 |
2022-02-09 |
Merck Sharp & Dohme |
Anticorps anti-pd-1 humain et procédés d'utilisation associés
|
|
JP7503056B6
(ja)
|
2018-11-07 |
2024-07-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
|
|
GB201906917D0
(en)
*
|
2019-05-16 |
2019-07-03 |
Intract Pharma Ltd |
Novel compositions
|
|
ES2992247T3
(es)
|
2020-01-08 |
2024-12-11 |
argenx BV |
Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
|
|
CN112451652A
(zh)
*
|
2020-12-07 |
2021-03-09 |
苏州智核生物医药科技有限公司 |
一种重组人促甲状腺素注射液
|
|
KR20250037789A
(ko)
|
2022-06-15 |
2025-03-18 |
아르젠엑스 비브이 |
Fcrn/항원-결합 분자 및 사용 방법
|